Iovance Biotherapeutics Investor Presentation — June 2019

Document content

Jefferies 2019 Global

Healthcare Conference

June 6, 2019This presentation contains “forward -looking” statements within themeaning offederal securities laws.These forward- looking statements

arenotstatements ofhistorical facts andarebased onmanagement’s beliefs andassumptions andoninformation currently available to

management .Forward- looking statements include information concerning theCompany’s business strategy andthedesign, progression

andtiming ofitsclinical trials .

Forward- looking statements generally canbeidentified byterms such as“expects,” “anticipates,” “believes,” “could,” “seeks,” “estimates,”

“intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” orsimilar expressions andthenegatives ofthose terms .

TheCompany’s operations involve risks anduncertainties, many ofwhich areoutside itscontrol, andanyoneofwhich, orcombination of

which, could materially affect itsresults ofoperations andwhether theforward -looking statements ultimately prove tobecorrect .Factors

thatmay materially affect theCompany’s results ofoperations andwhether these forward -looking statements prove tobecorrect include,

among other things, thatpreclinical testing may notbepredictive oftheresults orsuccess ofongoing orlater preclinical orclinical trials,

thatthedevelopment oftheCompany’s product candidates andnew platforms willtake longer and/or cost more than planned andthatthe

identification ofnew product candidates willtake longer than planned, aswellasthose listed inourQuarterly Report onForm 10-Qfiled

onMay 9,2019, with theSecurities andExchange Commission (“SEC”) andsubsequent SEC filings .Except asrequired bylaw, the

Company assumes noobligation toupdate these forward- looking statements publicly, ortoupdate thereasons actual results could differ

materially from those anticipated intheforward- looking statements, even ifnew information becomes available inthefuture.

Copies oftheCompany’s Quarterly Report onForm 10-Qandourother SEC filings areavailable byvisiting EDGAR ontheSEC website

athttp://www. sec.gov.Legal Disclaimer

2Building a Leading ADC Oncology Company

XMT-1536 –Lead Asset in

Proof-of-Concept (POC) Development

•Validated NaPi2b target

•First-in-class potential

•Encouraging Phase 1 dose data

•Planning to dose patients in Phase 1 dose expansion in 3Q19

Robust Discovery Effort Matching

Target to Appropriate Platform

•Plan to disclose next

clinical candidate in 4Q 2019

Preview truncated — download the full document for the complete content.